---
title: Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated
  With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation
date: '2024-07-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38986047/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240711181556&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: In summary, we developed and validated individual quantitative
  nomogram-based OS prediction. Continuous risk assessment integrating molecular prognostic
  factors is superior to R-ISS, R2-ISS, or Mayo-2022-score ...'
disable_comments: true
---
CONCLUSION: In summary, we developed and validated individual quantitative nomogram-based OS prediction. Continuous risk assessment integrating molecular prognostic factors is superior to R-ISS, R2-ISS, or Mayo-2022-score ...